Guggenheim Maintains Veracyte Buy Rating, Cuts Target Price to $35
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Stocks · News reference
Veracyte authorized a $100 million share repurchase program and adjusted its full-year 2026 revenue guidance to a range of $590 million to $593 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on Veracyte, Inc. while lowering the price target to $35.
Analyst Mason Carrico of Stephens & Co. has maintained an 'Overweight' (Buy) rating on Veracyte, Inc. while adjusting the price target.
Piper Sandler has maintained a Buy rating on Veracyte, Inc. while significantly reducing its price target for the company's stock.